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Abstract
Metastasis spreading confers a worse prognosis to the clinical outcome among patients suffering from osteosarcoma, the most
common primary bone tumor in childhood and adolescence. The detection of molecules involved in metastasis spreading might
contribute to understanding tumor dissemination mechanisms, thereby opening the way to novel therapeutic strategies. The Ezrin-
radixin-moesin (ERM) family proteins are activated after interacting with molecules belonging to the phosphoinositide signal trans-
duction pathway. The phosphatydil inositol (4,5) bisphosphate (PIP2), a crucial molecule in the PI pathway, stabilizes the ERM pro-
teins or a more efficient receptor binding. The PIP2 levels in the pathway are a critical element for regulating several cell events. The
PIP2 levels are regulated using enzymes, including the PI-specific Phospholipase C family. A decrease in the PIP2 levels induces the
dissociation of the ERM protein from the membrane. In this regard, the PI-PLC enzymes regulate this event. In this paper, the role
of the PI signal transduction molecules in osteosarcoma metastases is discussed.
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1. Context
Primary bone tumors are relatively uncommon, gen-
erally accounting for 0.2% of all malignancies and 0.3% of
cancer deaths (1). Bimodal age distribution with two peaks
of incidence is observed in bone tumors, the first of which
is noticed in childhood/adolescence, especially 10–14-year-
old aged patients, and the second of which is reported in
late adulthood, especially individuals aged above 65 years
and frequently suffering from Paget’s disease (2). Bone
tumors were classified according to the differentiation of
malignant cells based on a list of parameters such as cell
morphology, phenotype, and genotype (1).
Except for chondrosarcoma, osteosarcoma (OS) is the
most frequent primary bone tumor, accounting for about
16 - 17% of bone tumors (1). According to the literature, OS
comprises several tumors with slightly different clinical,
radiological, and histological features (2-4). Moreover, OS
affects 5/106 persons per year and represents the most dif-
fused primary bone tumor among children (5), accounting
for 5% of cancers and 8.9% of cancer-related deaths among
these individuals (6). Differences in its prevalence have
also been reported regarding gender, with annual preva-
lence rates of 5.4/106 and 4/106 among males and females,
respectively (6).
Several abnormalities are described in OS, making it
difficult to define its diagnosis, select an appropriate ther-
apy, and formulate the prognosis (7). The recognition of
specific OS variants is critical for the treatment of the pa-
tients (8). Epidemiology data, genomic/molecular charac-
terization, and studies in experimental models have pro-
vided helpful insights to OS management. Although many
research efforts have been made, the aetiology, pathogene-
sis, and natural history of OS are not well detected.
The present review study aimed to resume and discuss
the state of the art in the role of selected signal transduc-




OS seems to originate from osteoid-producing mes-
enchymal stem cells (MSCs), located in multiple com-
partments (7, 9). MSCs include adherent cells in the in-
tramedullary space and osteoblasts located along bone en-
dosteum and periosteum, which are actively involved in
fracture repairs and remodeling (10, 11).
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Malignant OS cells produce osteoid or immature
bone (2, 3), resulting in lesions that grow radially form
spheroidal masses. Such neo-formations penetratethe
bony cortex into a capsule-like layer, referred to as the re-
active zone, compressing the neighboring muscles. The ex-
tensions of the primary tumor, i.e., satellites, invade the re-
active zone. The tumor invasion induces bone weakness,
pain, swelling, tenderness, and fractures in the affected
area. Occasionally, lethargy, fever, weight loss, and anemia
are also observed (12).
Although OS can virtually develop in any bone, the pri-
mary tumor mostly triggers in the actively-growing meta-
physes of long bones (e.g., distally in the femur and proxi-
mally in the tibia and humerus). Differences in the tumor
site and patients’ survival rates seemingly depend on the
age at diagnosis (13, 14).
The tumor can diffuse regionally or spread to other
organs (15). About 20% of patients are referred to clin-
ics/hospitals with lung metastases at the moment of diag-
nosis. Otherwise, metastases can occur in about 40% of pa-
tients with nonmetastatic OS (12). The OS metastases pri-
marily colonize the lungs, and usually, after metastasis has
formed in the lungs, then metastases can occur in bones
different from the primary tumor. Metastases in distant
bones represent the last OS stage and are associated with
the poorest prognosis (12, 16). From this perspective, the
metastatic spreading is considered as a crucial aspect of
the OS progression.
The OS recognition is complex, and it is not often pos-
sible to make the diagnosis exclusively by radiologic exam-
ination. Histology observations and the consistent spec-
trum of clinical presentations help formulate the diag-
nosis, contributing to the so-called triple diagnostic ap-
proach, which is necessary to discriminate different OS fea-
tures.
Depending on the features of tumors, the OS treat-
ment includes a combination of surgeries, radiotherapy,
and chemotherapy. In this regard, the metastases aggra-
vate the prognosis (2), as metastasizing lesions partially re-
spond to therapies and are the leading cause of death (4).
Accordingly, both the progression of the disease and the
outcomes mainly depend on the metastatic potential of
OS, which has a high tendency to disseminate (2, 3).
2.2. Formation of Metastasis and Signaling
To develop a metastasis, the malignant cell must leave
the primary tumor site, migrate, survive within vessels, in-
vade, and colonize a secondary site. The molecular evo-
lution of cancer cells, while they are spreading, is still in
need of research as such metastases still are considered
as a challenge for personalized cancer therapy. Recently,
the concept ‘metastasome’ has been suggested to revise
the metastasis model and systematize both molecular and
functional features characterizing metastases differently
from primary tumors (17, 18).
The development of metastases is a complex phe-
nomenon with some sequential steps, and the acquisition
of motility is a central event for the malignant cell (5, 19-
21). The sequence of events ultimately enabling cells to
migrate results in the reorganization of the cytoskeleton,
which involves several signal transduction pathways such
as the Rho/Rac GTPase signaling (22, 23). The Rho/Rac GT-
Pase pathway induces membrane ruffles and is involved in
forming focal adhesion complexes and lamellipodia and
prompting cells to extend the protrusions requested for
movement (24). In invasive tumor cells, the components
of signaling pathways in the cytoskeleton architecture are
abnormally expressed (20, 21). Despite research efforts, the
intracellular mechanism regulating cell migration is not
well-understood.
The knowledge of the signal transduction systems act-
ing in the bone tissue, which can be dis-regulated during
the OS emergence and progression, might provide promis-
ing perspectives. The detection of molecules belonging to
signal transduction pathways might contribute to describ-
ing the natural history of the tumor and refine the progno-
sis, opening new ways to novel molecular-targeted thera-
peutic strategies.
From this perspective, Ezrin, a protein involved in reg-
ulating the cytoskeleton activity and the metastatic spread
of OS, has been of great interest (25).
2.3. Ezrin and OS Metastases
Ezrin belongs to the family of ERM proteins, which play
structural and regulatory roles in the assembly and sta-
bilization of specialized plasma membrane domains by
cross-linking plasma membrane proteins and actin fila-
ments (26). As a member of the ERM family, Ezrin pos-
sesses the Protein 4.1 ezrin, radixin, moesin (FERM) domain
(PBD ID:1GC6) (27). The N-terminus FERM domain is demon-
strated to interact with membrane/transmembrane pro-
teins and signaling molecules (27-29). Ezrin participates in
complex cell surface structures and is involved in some ac-
tivities, including the Rho GTPase-dependent signal trans-
duction pathway.
The imbalanced inactive versus active conformation
of the ERM proteins plays a key role in the conforma-
tional regulation of the link between cytoskeleton actin
and the plasma membrane (29, 30). The Ezrin activa-
tion is strictly regulated, mainly depending upon the
phosphorylation/de-phosphorylation imbalance. Ezrin
undergoes phosphorylation at two sites: (1) C-terminal
threonine (Thr 567) using enzymes bearing kinase activ-
ity such as Rho kinase (31), and (2) N-terminal tyrosines
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by means of receptor tyrosine kinases such as the epider-
mal growth factor receptor and c-MET (32, 33). This phe-
nomenon promotes the reorganization of the cytoskele-
ton, inducing morphogenetic and functional modifica-
tions in the cell. The un-phosphorylated Ezrin, located in
the cytoplasm, can be activated by phosphorylation and
moves and tether actin to the cortical membrane (34).
Evidence indicates that the absence of Ezrin (both ex-
pression and function disruption) decreases the OS spread-
ing. In experimental models, a significant decrease in the
metastatic dissemination was obtained after suppressing
Ezrin’s expression or disrupting its function by the use of
antisense transfection, the stable expression of short hair-
pin RNA, or the transfection of a dominant-negative Ezrin
(25, 26). The absence or reduction of Ezrin was associated
with a decrease in Akt and mitogen-activated protein ki-
nase (MAPK) activity (35). Moreover, the imbalanced acti-
vation/inactivation of the ERM proteins indirectly depends
on the calcium metabolism (36).
2.4. Ezrin and Calcium Signaling
The calcium concentration regulation is critical to
many physiological events; hence, a finely-tuned regula-
tion by a complex network of signaling pathways is re-
quired. Intracellular calcium plays a crucial role as a sec-
ond messenger in regulating cell apoptosis (37). Abnormal
calcium increase within the cell affects protein functions,
secretion, and contractility (37).
Calcium metabolism is regulated by the signaling
pathways, including the phosphoinositide (PI) transduc-
tion system (38). The phosphorylated PI derivative phos-
phatydil inositol (4,5) bisphosphate (PIP2), located in the
inner half of the membrane’s lipid bilayer, is of essence
for many cellular activities, including endo/exocytosis, cell
motility, and ion channel regulation. The PIP2 levels are
strictly regulated by converting enzymes (39), including
the PI-specific phospholipase C (PLC) family (37, 39). Great
attention has recently been paid to the PLC enzymes due
to their involvement in an increasing number of diseases
(40-43)
The calcium metabolism was demonstrated to be crit-
ical for the viability of human OS cell lines (2, 3) and the
relationship between Ezrin and PIP2. Depending on the N-
terminal domains, the ERM proteins can simultaneously
bind both actin and PIP2 (44-49). The conformation of
Ezrin is changed after it interacts with PIP2. The change
in Ezrin’s conformation activates ezrin (47). In this regard,
both phosphorylation and PIP2 binding allow the stabiliza-
tion of ERM proteins and/or ameliorate binding to recep-
tors (49-52).
As the Ezrin activity depends on membrane PIP2 lev-
els, PIP2-cleaving PLC enzymes play a critical role. PLCs are
required for the chemokine-mediated dissociation of ERM
proteins from the membrane (53). The decreased PIP2 lev-
els move ERM proteins to dissociate from the plasma mem-
brane. The inactivation follows the chemokine binding to
a GPCR, CXCR4, thus supporting the hypothesis indicating
that the PLC activation commonly results from GPCR sig-
naling (38).
2.5. The PI-specific PLC
The activation of PLC basically cleaves the polar head
group of PIP2, producing two further signaling molecules
(namely inositol trisphosphate (IP3) and diacylglycerol
(DAG)) (39).
As IP3 is water-soluble, it rapidly diffuses to the cyto-
plasm, binds IP3-gated calcium channels in the endoplas-
mic reticulum (ER) membrane, and induces calcium re-
lease from the ER. The calcium increase in the cytoplasm
initially propagates as a wave, followed by a series of cal-
cium spikes (39).
Binding to the membrane by using its fatty acid tails,
DAG can be cleaved into arachidonic acid to synthesize
eicosanoids (54) and activate serine/threonine calcium-
dependent protein kinase C (PKC) enzymes. Moreover, the
increased IP3-induced calcium moves PKC from the cyto-
plasm to the cytoplasmic face of the plasma membrane,
thereby activating and enabling PKC to phosphorylate fur-
ther target proteins (37, 39, 55).
The mammals’ PLC family comprises multi-domain
enzymes grouped into six sub-families based on the
amino acid sequences, domain structures, and recruit-
ment mechanisms: β(1-4), γ(1-2), δ(1, 3, 4), ε(1), ζ(1), and η(1-
2) (37).
The PLC enzymes, specifically PLC ζ , which is exclu-
sively described in the spermatic lineage (37), are cell-type
specific (56-58). The panel of PLC expression in each cell
varies under abnormal conditions, compared to the nor-
mal counterparts (43, 59, 60). The panel of PLC expression
was also modified by specific stimuli (61-63), including in-
flammation (64-66), or by some specific inhibitors (67, 68).
The subcellular distribution of the PLC enzymes influences
their activity, suggesting specific roles for each isoform be-
sides the cleavage of PIP2 (69-73). The PLC enzymes are in-
volved in some human diseases, including the nervous sys-
tem tumors (64, 65) and abnormalities (64, 74-79).
2.6. PLCs in the Bone
The PLC enzymes contribute to a broad spectrum of
regulatory interactions with receptor and non-receptor ty-
rosine kinases and the lipid components of cellular mem-
branes in all human tissues (37). A review of the literature
indicates how PLCs can specifically act in the complex bone
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Figure 1. PLC activity upon plasma-membrane PIP2
metabolisms. In this regard, the activation of PLC is impor-
tant in modulating the parathyroid hormone (PTH) (80).
PLCβ1 isoform might commit MSCs to differentiate into os-
teogenic lineage cells (81, 82). The interaction between the
calcitonin gene-related peptide (CGRP) and its own recep-
tor activates PLC β1 (83). Berberine hydrochloride targets
TRAF6 and NFATc1, inhibiting osteoclastogenesis, and bone
destruction also decreases the PLC γ1 levels (84). PLC γ2 is
demonstrated to be a key element in the early phases of
osteoclast differentiation, adhesion, and migration, thus
playing a role in bone resorption (85, 86). During autoim-
mune inflammation, PLC γ2 probably contributes to regu-
lating the cellular and molecular mechanisms in bone and
immune cells (87). Furthermore, PLC γ2 regulates the ac-
tivation of Proto-oncogene tyrosine-protein kinase Src (c-
Src) and membrane localization in osteoclasts (88).
Although reports have suggested that the PLC enzymes
may represent critical regulators in the bone adaptation,
their role is not well-explored.
2.7. PLCs in Human Osteoblast
Osteoblasts derive from MSCs and play a pivotal role in
secreting the matrix components of bones (89-91). Depend-
ing on many factors, the osteoblast can differentiate into
osteocytes (92) or chondroid bone-forming cells under spe-
cific conditions (93).
In osteoblasts, the selected PLC enzymes contribute to
regulating the calcium metabolism in a complex manner
(94-99). Following the mechanic stimulation, the nuclear
factor kB (NFkB) moves into the nucleus, under the PLC
control (100, 101).
In osteoblasts, a peculiar panel of the PLC expression is
reported (102). In this regard, PLCB1, PLCB3, PLCB4, PLCG1,
PLCG2, PLCD1, PLCD3, PLCD4, and PLCE are expressed, while
PLCH1 and PLCH2 are inconstantly expressed (Table 1).
Moreover, PLC β1, PLC β4, PLC γ1, PLC δ1, and PLC η1 en-
zymes are detected in the cytoplasm. PLC β3 and PLC
η2 are detected at the perinuclear and membrane lev-
els, respectively (102). Despite its absence, PLC β2 in os-
teoblasts transduces signals from prostaglandin E2 and
other prostanoids (103). Given the extremely low basal
expression, the PLC β2 expression seems to be correlated
with specific stimuli, including transforming signals (103),
as discussed above.
Although the PLC δ4 enzyme is not detected and a
PLCD4 transcript is expressed in osteoblasts and the Hs888
metastatic cell line, it is absent in other OS cell lines, includ-
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Table 1. Basal Expression of PLC Genes in Fibroblasts, Osteoblasts, and OS Cell Lines
OMIM Fibroblast Osteoblast MG-63 SaOS-2 Hs888 143B
PLCB1 *607120 + + + + + +
PLCB2 *604114 - - - - - -
PLCB3 *600230 + + + + + +
PLCB4 *600810 + + + + + +
PLCG1 *172420 + + + + + +
PLCG2 *600220 + + + + + +
PLCD1 *602142 + + + + + +
PLCD3 *608795 + + + + + +
PLCD4 *605939 + + - - + -
PLCE *608414 + + + + + +
PLCH1 *612835 - + - + + -
PLCH2 *612836 - + - - - -
ing MG-63 and SaOS-2 cells (102). Interestingly, PLCD4 was
inconstantly expressed in fibroblasts (58). The sub-family
isoforms of PLC δ, the most evolutionary ancient, and well
conserved (37), are highly sensitive to calcium and play a
key role in cell proliferation (37). The PLC δ4 involvement
is observed in response to nutritional and environmental
stress in yeast and plants (104, 105), and in stress-induced
response in human endothelial cells (61, 62, 65, 102). Com-
pared to normal resting liver, PLC δ4 is expressed at high
levels to regenerate liver in hepatoma and src-transformed
cells (106). Accordingly, PLC δ4, in cooperation with nu-
clear PKC α and ε regulates liver regeneration (107). The
PLC δ4 expression is probably associated with mitogenic
signals, so this isoform is expressed more abundantly in
high-rate proliferating cells (108), as discussed above. The
up-regulation of PLCD4 might regulate other PLC enzymes,
including PLCβ1 (109). This issue might be due to the high-
est sensitivity of PLC δ isoforms to calcium concentration.
Probably, the PLC δ4 activation by a small amount of cal-
cium induces an increase in the calcium levels to recruit
further PLC isoforms, implying an internal regulatory hi-
erarchy among the PLC enzymes.
Similarly, the PLC η isoforms, the most recently discov-
ered PLC family, show high sensitivity to calcium (37, 110).
PLC η1 as a signal amplifier plays a key role in calcium sig-
naling mediated by G protein-coupled receptors (GPCR).
The mobilization of ER intracellular calcium plays a pivotal
role in the PLC η1 activation (111), which is probably caused
by a positive feedback from PLC δ4 (66, 68). On the other
hand, PLC η2 is involved in regulating temporal and spa-
tial cell calcium dynamics (110), thus transducing calcium
signals from mitochondria. Osteoblasts, MG-63 cells, and
SaOS-2 cells seem to share a similar expression panel of the
PLC enzymes (65), with significant differences in express-
ing the PLC δ4 and PLC η subfamily isoforms.
2.8. PLC in Human OS Cell Lines
Previous reports analyzed the expression of PLCs in hu-
man bone tumors (68), with particular attention to OS.
This is because of the relationship between Ezrin and PLC,
which can interact with PIP2. The OS cell lines with differ-
ent molecular, histologic and clinical features have been
extensively researched (63, 65, 68, 77, 109).
As partially expected, the expression panel of PLC en-
zymes depends on a specific OS cell line (65). The MG-63
cells have low levels of alkaline phosphatase activity and
PTH unresponsive adenylate cyclase (112). Although the
MG-63 cell line is usually used as an experimental model
for human osteoblasts, the expression panel of PLCs dif-
fers from the panel described in osteoblasts, as in the other
OS cell lines (63, 68). The specific features of each OS cell
line partially explain different responses to therapy, prog-
nosis, and expression panel of PLCs. SaOS-2 epithelial-like
cells are also used as an experimental model for human os-
teoblasts (100, 113, 114). In this regard, 143B cells, thymidine
kinase negative, are considered highly aggressive and de-
velop osteolytic tumors (115). Hs888 cells are derived from
OS lung metastases (25).
Previous studies have indicated the expressions of PLC
β1, β3, γ1, γ2, and δ1 in some osteosarcoma cell lines, in-
cluding MG-63 and SaOS-2 cell lines (116, 117). More recent
studies have suggested that the MG-63 cell line expresses
PLC β1, β2, β3, γ1, γ2, β4, δ3, and δ1 (65). In the143B cell
line, PLC β1, β3, β4, γ1, γ2, δ1, δ3, and ε are also expressed;
however, PLCβ2 is weakly expressed. In the SaOS-2 cell line,
PLCβ1,β3, γ1, γ2, δ1,β4, δ3, ε and η1 are expressed, and PLC
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β1, β3, β4, γ1, δ1, δ3, δ4, and ε are expressed in the Hs888
cell line (65) (Table 1).
PLC β2, involved in mechanic transduction and cell at-
tachment, inconstantly described in osteoblasts (61, 103),
was weakly expressed in the MG-63 cell line (65). PLCβ2 was
not described in unstimulated cells (61, 116, 117), suggesting
that the basal expression is low, and increase might follow
to different and specific stimuli, both mechanic and bio-
chemical (103).
Enzymes belonging to the PLC γ subfamily are highly
expressed in tumors compared to normal tissues (118, 119),
thereby playing key roles in cell growth, survival, and
migration (120). Rho/Rac GTPases contributes to the cy-
toskeleton reorganization, thus enabling cells to extend
the protrusions requested for movement (22-24). PLC γ1, a
critical factor to develop and maintain tumor metastases,
is noticed in four human OS cell lines (65). PI3 kinases
(PI3Ks), together with Rac, regulates both polarization and
cell migration (24), contributes to activating PLC γ1 (121)
and translates to the leading edge of MDA-MB-231 migrat-
ing cells (117). In this regard, PLC γ1 probably acts as an
intracellular link between PI3K and Rac and regulates the
reorganization of actin by the Rac and WASP family pro-
teins (122). However, PLC γ1 can regulate cell migration by
further downstream effectors and directly activates cofilin
(123), which is also involved in the motility and invasion
of malignant cells. PLC γ1 can regulate cell migration and
invasion by modulating the activation of ERK acting as a
downstream effector (21). Moreover, the small interfering
RNA knockdown of PLCG1 in human prostate carcinoma
cell line (PC3LN3) affects cell adhesion (124). In breast can-
cer, the dissemination of malignant cells is correlated with
the PLC γ1 expression, and the absence of the enzyme af-
fects actin polymerization and focal adhesion modulat-
ing Rac (122). In addition to the critical role of PLC γ1 in
the metastasis formation, its down-regulation results in
metastases regression (122). Phospholipase C gamma1 is
required for metastasis development and progression, ex-
plaining the regression of micrometastasis.
PLCγ2 is expressed in MG-63, 143B, and SaOS-2 cell lines;
however, it is exclusively absent in Hs888 cell line (65). In
this regard, its concentration is estimated to be about 50%
higher in 143B and SaOS-2 cells than in MG-63 cells (65). This
may be justified based on the aforementioned role of PLC
γ2 in bone resorption during the differentiation of osteo-
clasts (85-87).
PLC δ4 has been expressed exclusively in Hs888 (65)
and in different tumors (40, 56, 64). In breast cancer cells,
the abnormal expression of PLC δ4 induces both the up-
regulation of ErbB and the activation of the ERK pathway
(125).
Regarding their features, Hs888 cells express PLC δ4
but not PLC γ2 (65). PLC η1, expressed in SaOS-2 and Hs888
cell lines (65), is essential for downstream ERK1/2 phos-
phorylation (111). Although the role of PLC η1 is not well-
investigated, its activation seems to enhance the GPCR-
mediated calcium pathway (111).
2.9. Ezrin and PLCs in OS
The abnormal expression of Ezrin is associated with
the poor prognosis in human tumors, suggesting its role
in tumor progression (126). Ezrin induces metastatic be-
havior in animal OS models (25), which may interfere with
apoptosis, cell adhesion, and/or Rho GTPases signaling
(127). PLCs induce ERM proteins to dissociate from the
membrane by reducing the PIP2 levels (53). Inactivation
follows chemokine’s binding to CXCR4, suggesting that
PLC activation is the outcome of the GPCR signaling (38).
Enzymes belonging to the PLC β sub-family are activated
by Rac, and PLCε is a downstream effector of Ras superfam-
ily GTPases and an upstream activator of small GTPases, in-
cluding both Ras and Rap (128) as key regulators in actin cy-
toskeleton rearrangement and tumor cell migration and
invasion (129-131). PLCs probably act as the convergence
point of the signaling pathways networking Rho and Ras
GTPases, which in turn regulate the Ezrin activity (36, 132).
From this perspective, a relationship between Ezrin with
the PLC enzymes and the metastatic progression of OS was
hypothesized.
Given the supposed role of Ezrin in tumor progression
and metastasis formation, silencing the expression of EZR
(OMIM *123900), a gene codifying for Ezrin protein, signifi-
cantly reduces the growth rate of both 143B and Hs888 cells
in a time-dependent manner, with the most marked effects
observed in the 143B cell line (61).
In the 143B cell line, the EZR silencing and the conse-
quent lack of Ezrin induce the up-regulation of PLCG2, the
down-regulation of PLCB1 and PLCE, and cell morphology
changes and reduce intercellular adhesion and cytoplasm
microvacuolization (109).
In the Hs888 cell line, EZR silencing induces the up-
regulation of PLCB1, PLCG2, and PLCD4, and cell morphol-
ogy changes such as decreasing the number of cells with
well-preserved structure. In the un-silenced control Hs888
cells, PLC β1 is mildly detected in the cytoplasm, while PLC
γ2 is absent. Following the Ezrin silencing,β1 significantly
increases in the cytoplasm PLC, and PLC γ2 is weakly de-
tected, mainly evident in the perinuclear region (109).
In the 143B cell line, EZR silencing reduces, while it en-
hances the transcription of PLCB1 in Hs888. Notably, in both
143B and Hs888 cell lines, PLCB1 is expressed at a low rate
(65). The expression of PLC β1 is selectively increased dur-
ing myoblast and adipocyte differentiation (133, 134) and
development (135) in breast cancer (120, 136). In high risk
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patients affected with myelodisplastic syndrome, the dele-
tion of PLCB1 is associated with poor outcome progressing
to acute myeloid leukemia (137, 138). In this regard, as PLCB1
loss favours myeloid lineage cancer (42, 137), it is specu-
lated that normal/increased PLCB1 may be a disadvantage
to malignant progression. The loss of Ezrin, which pro-
motes metastasis formation, induces the down-regulation
of PLC β1 in the most aggressive OS cell line, which may
favour malignancy. The variations in the PLCB1 expression,
which concomitantly occur with the Ezrin silencing, sug-
gest a relationship between the two molecules. This issue
deserves further studies.
The EZR silencing induces the up-regulation of PLCG2
transcription (109). The PLC γ sub-family isoforms bear a
unique region comprising two tandem SH2 domains and
one SH3 domain adjacent to a split Pleckstrin Homology
(PH) domain (139, 140). Notably, Ezrin interacts with the
SH2 domain, and reveals a relationship with PLC γ sub-
family (34). PLC γ2 is involved in the actin cytoskeleton
reorganization and Rac-activation in dendritic cells (141).
As previously discussed, PLC γ2 plays a critical role in the
osteoclast lineage, acting in the integrin-mediated adhe-
sion and migration (85), and in the activation of Proto-
oncogene tyrosine-protein kinase Src (c-Src) and mem-
brane localization (88). Actin binding proteins, which bind
PIP2, negatively regulate PLC γ2; hence, the up-regulation
of PLC γ2 following the EZR silencing might be associated
with the osteolytic nature of 143B cells as PLC γ2 acts in os-
teoclast formation and function (88) as well as in bone loss
modulation (141). In this regard, PLC γ2 is not detected in
Hs888. After EZR silencing, the transcript from PLCG2 is de-
tected, indicating that the regulation of PLC γ2 networks
Ezrin, independently from the OS cell line.
PLC δ4, exclusively expressed in the Hs888 OS cell line,
is up-regulated after the EZR silencing. In breast cancer
cells, the abnormal expression of PLC δ4 contributes to
carcinogenesis by up-regulating ErbB and activating the
ERK pathway (125) in response to mitogenic signals (108).
The up-regulation of PLCD4 in Hs888 following the EZR si-
lencing suggests a relationship between Ezrin and PLC δ4,
which seems to be associated with the contemporary up-
regulation of PLCB1 (109, 142).
In Hs888, the EZR silencing induced significant differ-
ences in the expression of PLCE (109). PLC ε plays a key
role in carcinogenesis, with an undefined mechanism of
action. The experimental loss of PLC ε inhibits the growth
of bladder tumor cells (143, 144), and the over-expression
of PLC ε is reported in murine skin cancer (145-147). PLC
ε is involved in the progression of head and neck cancer
(148), and one PLCE polymorphism is associated with squa-
mous cell carcinoma and gastric cancer (36). Controversial
reports have indicated both tumor-suppressing and pro-
moting activities for PLC ε, which may depend on the type
of tumor. Considering OS, the Ezrin silencing enhances the
expression of PLCE in the Hs888 cell line, suggesting a rela-
tionship between Ezrin and PLC ε. Microscopy observation
confirmed this hypothesis, suggesting that Ezrin and PLCε
focally and partially co-localize in the cytoplasm of the OS
cells (109).
Remarkably, in the OS cell lines, the EZR silencing modi-
fies the expression of PLC genes in a complex manner (109).
The overall reorganization of the expression panel of PLC
genes following the EZR silencing indicates a functional
connection between PLC and Ezrin. Further studies on the
relationship between Ezrin and selected PLC enzymes may
elucidate the crosstalk of signal transduction pathways in
OS.
2.10. Ezrin, PLC, and Ras GTPases
The selected PLC enzymes represent the conver-
gence point of pathways promoting Rho and Ras GTPase-
mediated signaling, which in turn regulates the Ezrin
activation. Among the wide spectrum of regulatory in-
teractions covered by the PLC family, theere has been
a great interest in direct binding to Ras GTPases (37-39,
149-151) regarding isoforms belonging to the PLC β and ε
sub-families.
The PH domain in the structure of enzymes belonging
to the PLCβ sub-family interacts with the Rho-GTPase fam-
ily member Rac, thus activating PLC (36). Rac1, involved in
actin polymerization, cell cycle regulation, and prolifera-
tion (152-155), can induce in vitro malignant transforma-
tion of the cell (156, 157). PLC ε is a direct effector for Rho
GTPases (158), directly and concomitantly activated by both
RhoA and individual Ras GTPases. Activation caused by a
variety of hormones, neurotransmitters, and growth fac-
tors results in the upstream control of signal transduction
pathways in the PLC ε downstream (37, 109).
Accordingly, isoforms belonging to the PLC β and ε
sub-families as well as Ezrin undergo Ras signaling reg-
ulation. On the other hand, both Ezrin and PLC recog-
nize and may competitively bind plasma membrane PIP2
molecules. A decrease in PIP2 induces Ezrin to relocate in
the cell (159); however, the inactivation of RhoA inhibits
such relocation, suggesting that RhoA might be involved
in the pathway upstream by either masking the actin bind-
ing site (160) or using a common downstream effector
(160). The expression of dominant negative Rac1 reduces
Ezrin at the level of adherens junctions (159).
The expression and the sub-cellular distribution of
RhoA and Rac1 change after silencing both EZR and PLCE
genes (142). Further, the PLC ε silencing acts differently
on the 143B and Hs888 cell lines depending on the differ-
ent features of the cells (142). The perinuclear relocation
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of Ezrin was associated with a decrease in RhoA and Rac1,
which may be caused by the PLC ε loss. RhoA and Rac1 are
differently expressed after the EZR silencing with respect to
the PLCE silencing. The modulation of RhoA is described in
the 143B cells proportionate to the PLC ε expression (142),
suggesting that RhoA and PLC εmay concurrently partici-
pate in the same pathway.
In the Hs888 cell line, there are decreases in Ezrin,
RhoA, and Rac1 simultaneous with an increase in PLC β1,
suggesting the different and complicated regulation of
Ezrin activity in Hs888 with respect to the other OS cell
lines. Moreover, the EZR silencing in Hs888 seems to affect
PLC genes, suggesting that Ezrin interacts with the same
isoforms under normal conditions. The other studies ad-
dressing the crosstalk and the ordered timing of action of
Ezrin and its networks in each OS cell line conclude that
PLCs and Ras GTPases may contribute to highlighting the
specific role of each molecule, providing new insights to
the metastatic progression of the disease and new thera-
peutic strategies.
2.11. Role of OS Upon Microenvironment
Analyzing the role of factors produced by cells in the
surrounding environment has recently offered promising
insights in some research fields. The cell microenviron-
ment encompasses molecules and factors, which can di-
rectly or indirectly act via biophysical, biochemical, or
other routes and influence the cell metabolism and sur-
vival, growth, apoptosis, and proliferation, Upon nearby
cells and distant immune cells (161). The detection of
the nature and activity of the molecules involved in the
microenvironment, including those belonging to signal
transduction systems, might help to understand both
physiological events and the systemic development of dis-
eases (162) since additional/abnormal components may
modify the morphological and functional features of cells
(163).
In tumors, factors released in the microenvironment
allow malignant cells to move from the primary tumor
site, migrate, and establish a new site (162). Malig-
nant cells can produce and release molecules in the mi-
croenvironment, and the immune system cells (e.g., cy-
tokines, chemokines and growth factors) respond to such
molecules. In vitro experiments have indicated that the
modification of the components in the microenvironment
interacts and affects the behaviour of both cells in the sur-
rounding normal tissues and cells belonging to the im-
mune system (162). Accordingly, the manipulation of the
microenvironment may provide promising perspectives
in terms of molecular therapy approaches. Immune sys-
tem cells can behave differently depending on the signal
transduction pathways acting in the microenvironment.
In this regard, the OS supernatants have recently been used
in vitro to modify the microenvironment (164).
The OS-derived supernatants are used to culture the
THP-1 cells currently used as an experimental model in ex-
amining the monocytes/macrophage lineage differentia-
tion (165). Supernatants from the cultured OS cell lines
contain cytokines/chemokines and affect the cell survival
and proliferation, induce differentiation, and modify the
expression panel of the PLC enzymes (164). More specifi-
cally, the panel of cytokines differs depending on the OS
cell line and differently affects the cell growth, prolifera-
tion, and survival.
The most remarkable effect on the growth rate of THP-
1 cells is observed for the supernatant from the highly ag-
gressive 143B cell line (115). The OS supernatants modify the
morphological and functional features of the THP-1 cells,
inducing differentiation into macrophages. This is prob-
ably due to the cytokines and chemokines released in the
supernatants. In this regard, IL-2, IL-6, IL8, TNFα, and GM-
CSF are detected in supernatants from MG-63, 143B, and
Hs888 cell lines, and IL-1α and IL-1β are identified in the
supernatants from 143B cell line (164). IL-2 is a central fac-
tor in controlling the immune response, and the remain-
ing cytokines play pro-inflammatory roles (166). Both GM-
CSF and TNF-α induce the differentiation of THP-1 into den-
dritic cells (165, 167).
Previous reports demonstrated that, the PLC enzymes
are differently expressed in un-polarized M0, M1, and M2
macrophages (63). THP-1 cells express all PLC isoforms,
with the exception of PLC (164). The supernatants from the
OS cell lines reduce the expression of PLCs in THP-1 cells
with particular attention to some isoforms, but with the
remarkable exception of PLCB3 (164). The modification of
PLCs’ expression slightly varies depending on the OS cells
line, which in general decreases the transcription of se-
lected isoforms.
The supernatant from the cultures of 143B cells reduces
the expression of all PLC isoforms, including PLCD4 and
PLCE that are not expressed. The supernatant from MG-63
cells block the transcription of PLCB1, PLCD4, PLCE, PLCH1,
and PLCH2 and reduces the transcription of the remaining
isoforms.
The supernatant from the cultures of HS888 cells
blocks the transcription of PLCB1, PLCG2, PLCD4, PLCE, PLCH1,
and PLCH2 and reduces the transcription of most of the
other isoforms. The only exception is PLCB3, which is
slightly increased. The supernatant from the cultures of
MG-63 cells block the transcription of PLCB1, PLCD4, PLCE,
PLCH1, and PLCH2, and the other isoforms are reduced. In
this regard, the decrease is significant for PLCB1 and PLCG2.
PLCB1 and PLCG2 genes codify for isoforms belonging
to primary PLCs, respectively PLC β1 and PLC γ2. PLC β1,
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involved in myocyte (133) and adipocyte differentiation
(134), is correlated with Cyclin D3, which regulates signal-
ing pathways acting in macrophages (168). The loss of PLC
β1 heterozygosity acts upon the leukemic progression of
myelodysplastic syndrome (42, 137). PLC β1 is also sug-
gested to be involved in cell migration, as discussed in the
next paragraph. PLC γ2 is highly expressed in cells belong-
ing to the hematopoietic lineage and mainly acts in the
immune system regulation (169, 170). Mutations in PLCG2
gene lead to auto-inflammatory diseases with immunode-
ficiency (171). PLC δ4 is expressed in response to mitogenic
stimulation acting in cell growth and tumorigenesis, and
PLC ε is involved in Ras and Rho signaling (172).
Accordingly, the block of transcription of PLC genes
in the 143B cell line might suggest that OS supernatants
are involved in the differentiation of THP-1 cells into
macrophages. According to some researchers (63), these
isoforms may represent the markers of macrophage differ-
entiation. The PLCB3 gene in HS888 cells slightly increases
and is the only one up-regulated isoform. The PLC β3 en-
zyme is expressed in some tissues (37) and is an upstream
target of protein kinase C ε. PLC β3 is involved in the
inflammatory response (173) and is a key to macrophage
survival (174). PLCB3 silencing potentiates the Toll-like re-
ceptor’s inflammatory signaling cascade in cystic fibrosis
bronchial epithelial cells, also inducing IL-8 release (175).
To sum up, the OS supernatants mimic the variations
that in vivo OS may drive in the microenvironment. Most
likely, OS supernatants contain further factors other than
the aforementioned cytokines. The effects of OS super-
natants on the proliferation and differentiation of THP-1
and the expression of PLC enzymes suggest that tumors
can modify the microenvironment composition. The ef-
fects of the OS supernatants on the THP-1 cells confirm that
modifications in the microenvironment can affect the im-
mune system cells and probably interfere with the progres-
sion of the diseases.
2.12. Extracellular Vesicles from OS
The role of extracellular vesicles (EVs), a recently iden-
tified mechanism of communication among cells, has pro-
vided promising insights into the research. EVs are par-
ticles coated by a membrane lipid-bilayer produced by
the cell and released in the microenvironment (176). The
lumen of EVs, surrounded by its own membrane, con-
tains molecules such as DNA, RNA, miRNA, and proteins,
derived and transferred out from the cell (177). Thanks
to EVs’ transfer, a cell can act upon other cells located
in the surrounding tissue and/or in distant target or-
gans. Furthermore, malignant cells can share membrane
molecules, intracellular proteins, and genetic informa-
tion, which might underlie events leading to metastasis
formation (178). More recently, research has addressed the
proteins/phospholipids in the EVs’ membrane, and PLC en-
zymes are described in the EVs produced by human os-
teoblasts and OS cell lines (179).
Osteoblasts and OS cell lines release PLCs-containing
EVs at different levels, suggesting that EVs in the bone are
used by the cell to vehicle PLC enzymes and transduce sig-
nals (179). The expression panel of PLCs and their localiza-
tion inside the EVs slightly differ depending on the specific
cell lines.
All PLC isoforms are detected in EVs from osteoblasts
and OS cells; however, they are differently localized in the
vesicle compartments. As PLC enzymes work at the cell
membrane and EVs are vesicle coated with cell membrane,
we expected to find them in the EVs. Some PLCs are de-
scribed both in the EV’s membrane and as cargo, others in
the membrane or within the vesicle (179).
More evidently, PLC β1 is conveyed by EVs in OS cells
compared to control osteoblasts, suggesting a role in EV-
mediated effects. In addition to the aforementioned roles
of PLC β1 and its role in metastatic cell migration through
lipid-dependent sequestration of cofilin (180), both PLC β1
and PLC η2 are described in HUVEC podosome-like struc-
tures, suggesting their involvement in cytoskeleton re-
modeling and subsequent cell migration (66).
The PLC γ sub-family is probably involved in the early
steps of cell migration. In addition to the aforementioned
roles, PLC γ isoforms induce actin polymerization leading
to the formation of cell protrusions, involved in sticking
to the extracellular matrix, controlling migration direc-
tion, and initiating cell crawling (181). PLC γ2 was identi-
fied in the EV’s membrane, more markedly in the 143B cell
line (179), corroborating the previous hypothesis indicat-
ing that PLC γ2 plays a role in aggressiveness (115, 142).
The presence of PLC enzymes in EVs suggests that Os-
teosarcoma can affect both the surrounding microenvi-
ronment and distant target cells, providing the niche for
metastasis. Further studies are recommended to investi-
gate the role of EV-mediated PLC signaling, both in the mi-
croenvironment and in reservoir cells, to provide insights
into issues leading to the OS spreading. Different levels and
differently-located PLCs containing EVs are produced by os-
teoblasts and each specific OS cell line, opening promising
perspectives. Futures researchers are suggested to address
this issue in detail. In this regard, EVs collected from blood
and the content of their PLCs might be used as diagnostic
biomarkers for OS and might be used as a prognostic fea-
ture to monitor progress.
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3. Conclusions
Metastasis spreading aggravates the prognosis of the
clinical outcomes in patients affected with OS. Despite
many research efforts and recent improvements, the
identification of factors and molecules involved in the
metastatic spreading of the OS tumors is largely unknown.
Accordingly, detecting the origin, behavior, interconnec-
tions, and interactions of molecules involved in the for-
mation of metastases may contribute to understanding
the tumor dissemination mechanisms, opening the way to
novel therapeutic strategies. The prominent role of Ezrin
and its relationship with both the PI signal transduction
pathway and the complex Ras GTPase system provide new
insights into issues leading to metastasis formation in OS,
opening promising perspectives to refine the prognosis
and develop new targeted molecules for therapy.
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